European Pharmacopoeia
The legally binding compendium for medicines and their components in the states party to the Convention on the Elaboration of a European Pharmacopoeia. Comprises general chapters, general monographs and specific monographs, and is maintained by EDQM under the Council of Europe with periodic supplements.
What this does not cover
stated in the document's own scope- Sets the quality standards for substances and preparations; it does not grant marketing authorisations, which are issued by the competent authorities.
- Applies to substances and dosage forms with a monograph or general requirement; a substance with no applicable monograph is controlled by the dossier specification.
- Is the European compendium; the corresponding US compendium is the USP–NF, and the two differ where methods are not harmonised.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The European Pharmacopoeia (Ph. Eur.) is the legally binding compendium of quality standards for medicines and their constituents in the states party to the Convention on its elaboration. It is built from general chapters (analytical methods and general requirements), general monographs (which apply to whole classes such as substances for pharmaceutical use or a given dosage form), and specific monographs (which set the identity, purity, and assay requirements for individual substances and preparations). It is maintained by the EDQM under the Council of Europe and is kept current through a numbered edition supplemented several times a year.
Scope & applicability
Any medicinal product or substance placed on the market in a Ph. Eur. signatory state. Where a monograph exists, compliance is a legal requirement rather than a recommendation.
Legal basis & how it acquires force
The Ph. Eur. is established under the Convention on the Elaboration of a European Pharmacopoeia, an international treaty administered by the Council of Europe. Unlike the USP, its monographs are legally binding in the signatory states by virtue of the Convention and of EU pharmaceutical law, which requires medicinal products and their ingredients to comply with the relevant Ph. Eur. monographs. A substance or preparation with a Ph. Eur. monograph must meet it to be of pharmacopoeial quality in those states — the monograph is the legal quality standard, not merely a reference.
Document structure
| Part | Covers |
|---|---|
| General chapters | General analytical methods, tests, and general requirements referenced throughout the monographs |
| General monographs | Requirements applying to entire classes, e.g. Substances for pharmaceutical use, or a dosage form |
| Specific monographs | Identity, purity, and assay requirements for individual active substances, excipients, and preparations |
| General notices | How the monographs are to be read and applied, including tolerances and interpretation |
| Supplements | The periodic updates that keep the current numbered edition in force |
Key requirements
- Testing against the current monograph, general monographs and applicable general chapters
- Version control over the Ph. Eur. edition and supplement in force
- Justification and validation where an alternative method is used in place of the compendial one
Implementation tips
- Track supplements as a controlled change: a revised monograph is a specification change, not an administrative update
- Where a product is supplied to both US and EU markets, document the Ph. Eur./USP comparison rather than assuming equivalence
- Confirm the current edition and supplement level before citing a monograph in a submission or a specification
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The Ph. Eur. is one of the three major pharmacopoeias, and many of its general test methods are harmonised with the USP and the Japanese Pharmacopoeia through the Pharmacopoeial Discussion Group. It is the standard the EDQM’s CEP procedure certifies substances against, and it underpins EU marketing authorisations. Where a Ph. Eur. monograph exists it takes legal precedence over a national pharmacopoeia in the signatory states.
Ph. Eur.: frequently asked questions
Quick answers to common questions about Ph. Eur..
Is the European Pharmacopoeia legally binding?
Yes. Unlike the USP, Ph. Eur. monographs are legally binding in the states party to the Convention on the Elaboration of a European Pharmacopoeia, reinforced by EU pharmaceutical law that requires compliance with the relevant monographs.
Who maintains the Ph. Eur.?
The EDQM (European Directorate for the Quality of Medicines & HealthCare) under the Council of Europe. It is issued as a numbered edition and kept current through supplements published several times a year.
What is the difference between a general monograph and a specific monograph?
A general monograph sets requirements applying to a whole class of substances or a dosage form; a specific monograph sets the identity, purity, and assay requirements for one named substance or preparation.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.